In this analysis, DFP appeared to be the most cost-effective treatment available for managing chronic iron overload in β-thalassaemia patients.
DFP had >99 % likelihood of being cost effective against all comparators at a willingness-to-pay threshold of £20,000 per QALY. Sensitivity analysis showed that DFP dominated all other treatments unless the QoL burden associated with the route of administration was greater for DFP than for DFO, which is unlikely to be the case. Assumptions that DFP conferred no cardiac morbidity, mortality, or morbidity and mortality benefit were also explored in scenario analysis.ĭFP was the dominant strategy in all scenarios modelled, providing greater QALY gains at a lower cost. Incremental costs and quality-adjusted life-years (QALYs) were calculated for each treatment, with cost effectiveness expressed as incremental cost per QALY. Healthcare resource use, drug costs (2010/2011 costs), and utilities associated with adverse events were also considered, with the effect of varying all parameters assessed in sensitivity analysis. Published utility scores for route of administration were used, with subcutaneously administered DFO assumed to incur a greater quality of life (QoL) burden than the oral chelators DFP and DFX.
Dfo three kingdoms trial#
Based on published randomized controlled trial evidence, it was assumed that all four treatment regimens had a comparable effect on serum ferritin concentration (SFC) and liver iron concentration (LIC), and that DFP was more effective for reducing cardiac morbidity and mortality. This study evaluated the relative cost effectiveness of these regimens over a 5-year timeframe from a UK National Health Service (NHS) perspective, including personal and social services.Ī Markov model was constructed to evaluate the cost effectiveness of the treatment regimens over 5 years. Many biomedical applications have been developed, most prominently the use of the. Research on these molecules has a continuing history over the past 50 years. Siderophores are low molecular weight chelators produced by bacteria and fungi to scavenge essential iron. Chronic iron overload can be treated using iron-chelating therapies such as desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) monotherapy, or DFO-DFP combination therapy. This review covers publications on siderophores applied for molecular imaging applications, mainly for radionuclide-based imaging. Euro 2020 will be broadcast in English on ESPN in the United States and on TSN in Canada. DFO-Coast Guard is modernizing fisheries, aquaculture, and responsible economic development on all three coasts by expanding on the successes of the Atlantic Fisheries Fund (AFF) through the creation of the British Columbia Salmon Restoration and Innovation Fund and Quebec Fisheries Fund. We will also provide previews of all the Copa Amrica countries as the Copa Amrica starts on Jright after Euro 2020 starts. Patients with β-thalassaemia major experience chronic iron overload due to regular blood transfusions. From now until the tourney starts, we’ll be giving you previews for every country in Euro 2020, DFO-style, of course.
0 kommentar(er)
